KONINKLIJKE PHILIPS NV EUR0.20KK

KONINKLIJKE PHILIPS NV EUR0.20

24.80EURD
+0.77+3.20%
At close at Feb 24, 18:18 GMT
EUR
No trades
See on Supercharts

0LNG fundamentals

Key facts

Market capitalization‪22.68 B‬EUR
Basic EPS (TTM)−0.76EUR
Founded1998
Employees (FY)‪67.82 K‬
CEORoy Jakobs
About

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Ownership
‪‪925.01 M‬‬
Free Float shares
‪‪762.52 M‬‬ (82.43%)
Closely held shares
‪‪162.49 M‬‬ (17.57%)
Free Float shares
‪‪762.52 M‬‬ (82.43%)
Closely held shares
‪‪162.49 M‬‬ (17.57%)
Capital structure
Market cap
‪‪22.68 B‬‬
Debt
‪‪7.64 B‬‬
Minority interest
‪‪37.00 M‬‬
Cash & equivalents
‪‪2.40 B‬‬
Enterprise value
‪‪27.95 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪22.68 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.21x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.21x
Valuation ratios
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪0.35‬
‪0.70‬
‪1.05‬
‪1.40‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−15%‬
‪−10%‬
‪−5%‬
‪0%‬
‪5%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−3.50 B‬‬
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−3.50 B‬‬
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−3.50 B‬‬
‪0.00‬
‪‪3.50 B‬‬
‪‪7.00 B‬‬
‪‪10.50 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Diagnosis & Treatment
Connected Care
Personal Health
Other
By country
Period: 2024
United States
Other Countries
Netherlands
China
Japan
Germany

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '22
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪2.10 B‬‬
‪‪4.20 B‬‬
‪‪6.30 B‬‬
‪‪8.40 B‬‬
Estimate
Earnings
Next:
H1 '22
H2 '23
H1 '24
H2 '24
‪0.00‬
‪0.10‬
‪0.20‬
‪0.30‬
‪0.40‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Next payment
0.212
Next ex-date
May 12, 2025
Dividend history
‪0.0%‬
‪0.7%‬
‪1.4%‬
‪2.1%‬
‪2.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.20‬
‪0.40‬
‪0.60‬
‪0.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−3.00 B‬‬
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪5.00 B‬‬
‪‪10.00 B‬‬
‪‪15.00 B‬‬
‪‪20.00 B‬‬
Assets
Liabilities